Stuart Therapeutics, Inc. (“Stuart”) today announced that it has entered into a license agreement with Glaukos Corporation (“Glaukos”) under which it has granted Glaukos exclusive worldwide rights to develop and commercialize Stuart’s proprietary ST-113 drug candidate for neuroprotection in glaucoma.
|
[18-October-2023] |
STUART, Fla., Oct. 18, 2023 /PRNewswire/ -- Stuart Therapeutics, Inc. (“Stuart”) today announced that it has entered into a license agreement with Glaukos Corporation (“Glaukos”) under which it has granted Glaukos exclusive worldwide rights to develop and commercialize Stuart’s proprietary ST-113 drug candidate for neuroprotection in glaucoma. ST-113 is a patented pre-clinical asset that has demonstrated the ability to provide neuroprotection and neuro-repair of optic nerve axons in animal testing and represents one of the leading candidates for a therapeutic approach to glaucoma that is independent of control of intraocular pressure, and that may provide a solution to normal tension glaucoma. Stuart Therapeutics Licenses its Glaucoma Neuroprotection Candidate to Glaukos Corporation Under the agreement, Stuart will receive an upfront payment, and is eligible for additional development and sales related milestone payments, plus royalties. Glaukos will assume all costs for development of ST-113. “We are thrilled to have joined forces with Glaukos to develop the first neuroprotective therapeutic targeting the extracellular matrix, which based on our research plays an important role in glaucoma. We wanted to partner with a leader in glaucoma therapeutics to bring this innovative drug candidate to the millions of glaucoma patients across the world, and Glaukos has delivered in this important disease area. They bring critical focus on novel therapies, capabilities in drug product design and delivery, and commercial strength worldwide. Stuart Therapeutics is proud to work with Glaukos on this important program,” said Eric Schlumpf, President and Chief Executive Officer of Stuart. About ST-113 About Glaucoma About Stuart Therapeutics View original content to download multimedia:https://www.prnewswire.com/news-releases/stuart-therapeutics-announces-exclusive-worldwide-license-agreement-with-glaukos-corporation-301961150.html SOURCE Stuart Therapeutics |